Elucidating Determinants of Survival Disparities Among a Real-world Cohort of Metastatic Breast Cancer Patients: A National Cancer Database Analysis
- PMID: 32434711
- DOI: 10.1016/j.clbc.2020.04.002
Elucidating Determinants of Survival Disparities Among a Real-world Cohort of Metastatic Breast Cancer Patients: A National Cancer Database Analysis
Abstract
Background: Disparities in breast cancer survival by race/ethnicity and socioeconomic status have been reported. However, it is unclear if these findings are reproducible among subpopulations. This study aimed to assess if socially oriented factors are predictive of overall survival (OS) among patients with hormone receptor-positive (HR+), human epidermal growth factor 2-positive (HER2+) metastatic breast cancer (MBC).
Patients and methods: We analyzed patients with MBC included in the National Cancer Database diagnosed with HR+ and HER2+ disease treated between 2010 and 2015. Multivariate analyses describe the association between non-clinical prognostic factors and OS. A matched analysis, which balanced prognostic factors between whites and African Americans (AA), was also conducted.
Results: Of the 6200 patients analyzed, the majority were 50 years or older, white, and treated with hormonal therapy. Disparities in OS were observed; multivariate analysis revealed diminished survival was associated with low income (< $38K vs. ≥ $63K, hazard ratio [HR], 1.30; P < .001), having government insurance (government vs. private, HR, 1.55; P < .001), living closer to one's treatment facility (< 4 miles vs. ≥ 18 miles, HR, 1.16; P = .04), and being AA (AA vs. white, HR, 1.20; P = .006). The mortality disparity attributed to race was insignificant in the matched analysis (AA vs. white, HR, 1.13; 95% confidence interval, 0.98-1.30; P = .09).
Conclusions: This study confirms that the known sociodemographic disparities in OS among patients with MBC are similar within the HR+/HER2+ subpopulation. The discordance of outcomes between matched and unmatched analysis demonstrate that there is a highly vulnerable subgroup of AAs. Further investigation is required to determine if the identified associations are independently causal of poor prognosis.
Keywords: Breast neoplasms; Healthcare disparities; NCDB; Socioeconomic factors; Survival analysis.
Copyright © 2020 Elsevier Inc. All rights reserved.
Similar articles
-
Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer.Breast Cancer Res Treat. 2013 Oct;141(3):461-70. doi: 10.1007/s10549-013-2697-5. Epub 2013 Sep 24. Breast Cancer Res Treat. 2013. PMID: 24062208 Free PMC article.
-
Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs.Clin Cancer Res. 2020 Mar 1;26(5):1105-1113. doi: 10.1158/1078-0432.CCR-19-2350. Epub 2019 Nov 26. Clin Cancer Res. 2020. PMID: 31772121
-
Hormone Receptor-Positive Breast Cancer Has a Worse Prognosis in Male Than in Female Patients.Clin Breast Cancer. 2017 Aug;17(5):356-366. doi: 10.1016/j.clbc.2017.03.005. Epub 2017 Apr 28. Clin Breast Cancer. 2017. PMID: 28576631
-
Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis.JAMA Netw Open. 2020 Oct 1;3(10):e2020312. doi: 10.1001/jamanetworkopen.2020.20312. JAMA Netw Open. 2020. PMID: 33048129 Free PMC article.
-
Racial Differences in Breast Cancer Survival Between Black and White Women According to Tumor Subtype: A Systematic Review and Meta-Analysis.J Clin Oncol. 2024 Nov 10;42(32):3867-3879. doi: 10.1200/JCO.23.02311. Epub 2024 Sep 17. J Clin Oncol. 2024. PMID: 39288352
Cited by
-
Breast Cancer in the United States: A Cross-Sectional Overview.J Cancer Epidemiol. 2020 Oct 30;2020:6387378. doi: 10.1155/2020/6387378. eCollection 2020. J Cancer Epidemiol. 2020. PMID: 33178276 Free PMC article.
-
Racial inequities in second-line treatment and overall survival among patients with metastatic breast cancer.Breast Cancer Res Treat. 2022 Nov;196(1):163-173. doi: 10.1007/s10549-022-06701-5. Epub 2022 Aug 26. Breast Cancer Res Treat. 2022. PMID: 36028783 Free PMC article.
-
Assessing equity of care across metastatic breast cancer treatment junctures: a multi-site retrospective cohort study.BMC Cancer. 2025 May 12;25(1):861. doi: 10.1186/s12885-025-14172-2. BMC Cancer. 2025. PMID: 40355843 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous